Shares Magazine
1.77p+0.05 (+2.91%)20 Sep 2024, 17:15
Jump to:
Immupharma PLC Fundamentals
| Company Name | Immupharma PLC | Last Updated | 2024-09-20 |
|---|---|---|---|
| Industry | Biotechnology | Sector | Healthcare |
| Shares in Issue | 416.437 m | Market Cap | £7.37 m |
| PE Ratio | 0.00 | Dividend per Share | 0 |
| Dividend Yield | 0 | Dividend Cover | 0 |
| EPS | -£0.01 | EPS Growth (%) | 0 |
| PEG | 0 | DPS Growth (%) | 0 |
| Debt Ratio | 0 | Debt Equity Ratio | 0 |
| Asset Equity Ratio | 1.5096 | Cash Equity Ratio | 0.4030 |
| Quick Ratio | 1.0450 | Current Ratio | 1.60 |
| Price To Book Value | 2.7390 | ROCE | 0 |
Immupharma PLC Dividends
| Type | Ex-Date | Pay Date | Currency | Net Dividend | Year Total |
|---|
Immupharma PLC Company Financials
| Assets | 2023 | 2022 | 2021 |
|---|---|---|---|
| Tangible Assets | £102,075.00 | £389,718.00 | £352,996.00 |
| Intangible Assets | £447,571.00 | £473,892.00 | £477,553.00 |
| Investments | £643,781.00 | £688,350.00 | £1.21 m |
| Total Fixed Assets | £1.38 m | £1.64 m | £2.65 m |
| Stocks | 0 | 0 | 0 |
| Debtors | £451,546.00 | £649,401.00 | £373,253.00 |
| Cash & Equivalents | £208,481.00 | £667,813.00 | £1.65 m |
| Other Assets | £184,785.00 | £83,790.00 | £612,997.00 |
| Total Assets | £2.72 m | £3.97 m | £6.00 m |
| Liabilities | 2023 | 2022 | 2021 |
|---|---|---|---|
| Creditors within 1 year | £1.67 m | £1.45 m | £1.58 m |
| Creditors after 1 year | 0 | 0 | 0 |
| Other Liabilities | 0 | 0 | 0 |
| Total Liabilities | £1.67 m | £1.45 m | £1.58 m |
| Net assets | £1.06 m | £2.52 m | £4.41 m |
| Equity | 2023 | 2022 | 2021 |
|---|---|---|---|
| Called up share capital | £29.81 m | £28.98 m | £28.50 m |
| Share Premium | £29.32 m | £28.79 m | £27.24 m |
| Profit / Loss | -£3.42 m | -£4.46 m | -£8.94 m |
| Other Equity | £1.06 m | £2.52 m | £4.41 m |
| Preference & Minorities | 0 | 0 | 0 |
| Total Capital Employed | £1.06 m | £2.52 m | £4.41 m |
| Ratios | 2023 | 2022 | 2021 |
|---|---|---|---|
| Debt Ratio | 0 | 0 | 0 |
| Debt-to-Equity | 0 | 0 | 0 |
| Assets / Equity | 1.5096 | 1.5096 | 1.5096 |
| Cash / Equity | 0.4030 | 0.4030 | 0.4030 |
| EPS | -£0.01 | -£0.01 | -£0.02 |
| Cash Flow | 2023 | 2022 | 2021 |
|---|---|---|---|
| Cash from operating activities | -£1.36 m | -£2.35 m | -£4.83 m |
| Cashflow before financing | -£642,311.00 | -£799,335.00 | -£4.13 m |
| Increase in Cash | -£453,549.00 | -£876,759.00 | -£4.18 m |
| Income | 2023 | 2022 | 2021 |
|---|---|---|---|
| Turnover | 0 | 0 | £118,350.00 |
| Cost of sales | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 |
| Operating Profit | -£3.06 m | -£3.03 m | -£6.59 m |
| Pre-Tax profit | -£3.42 m | -£4.46 m | -£8.94 m |
Immupharma PLC Company Background
| Sector | Healthcare |
|---|---|
| Activities | ImmuPharma PLC is a drug discovery and development company. The pipeline of the company includes novel peptide-based therapeutics within two therapy areas: autoimmunity & inflammation, and anti-infectives. The company's drug candidate is Lupuzor, which treats lupus, a life-threatening autoimmune disease. |
| Latest Interim Date | 9 Sep 2024 |
| Latest Fiscal Year End Date | 5 Jun 2024 |
Immupharma PLC Directors
| Appointed | Name | Position |
|---|---|---|
| 2021-07-30 | Dr. Franco Di Muzio | Non-Executive Director |
| 2006-03-31 | Mr. Douglas Gordon James Paterson | Non-Executive Director |
| 2024-03-19 | Mr. Timothy Paul McCarthy | Executive Director,Chairman and Chief Executive Officer |
| 2021-07-30 | Mr. Dimitri Dimitriou | Executive Director,Chief Executive Officer |
| 2021-05-24 | Dr. Robert Henri Zimmer | Executive Director,President and Chief Scientific Officer |
| 2016-05-05 | Mr. Richard Leonard Warr | Executive Director,Chairman |
| 2016-05-05 | Dr. Ajay Agrawal | Non-Executive Director |
| 2011-08-09 | Mr. Paddy Hugh Walker-Taylor FCA,MCT | Executive Director,Chief Financial Officer |
| 2006-03-31 | Mr. Anthony Johnson B.Pharm,MSc | Non-Executive Director |
| 2023-08-11 | Dr. Sanjeev Pandya | Non-Executive Director,Senior Independent Director |
| 2021-07-30 | Dr. Stephane Robert George Mery | Non-Executive Director |
| 2024-03-19 | Mr. Timothy Gary Franklin | Executive Director,Chief Operating Officer |
| 2024-04-19 | Ms. Lisa Baderoon | Non-Executive Director |
Immupharma PLC Contact Details
| Company Name | ImmuPharma PLC |
|---|---|
| Address | One Bartholomew Close, London, EC1A 7BL |
| Telephone | +44 2071524080 |
| Website | https://www.immupharma.co.uk |
Immupharma PLC Advisors
| Stockbroker | Bryan, Garnier & Co Limited |
|---|---|
| Phone | +44 2073322500 |
| Nominated Adviser | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Stockbroker | Northland Capital Partners |
|---|---|
| Phone | +44 2038616625 |
| Fax | +44 2076005975 |
| Registrar | Computershare Investor Services PLC |
|---|---|
| Phone | +44 3707020003 |
| Fax | +44 3707036101 |
| Auditor | Nexia Smith & Williamson |
|---|---|
| Phone | +44 2071314000 |
| Fax | +44 2071314001 |
| Solicitor | Bircham Dyson Bell |
|---|---|
| Phone | +44 2072277000 |
| Fax | +44 2072223480 |
| Bank | Royal Bank of Scotland PLC |
|---|
| Auditor | Nexia Smith & Williamson Audit Limited |
|---|
Receive our
daily news email
Subscribe to the latest investing news by entering your email address below
You can opt out at any time.
For five days a week you will get
- The latest company news
- Insight into investment trends
- Round-up of director's buys and sells
- Articles from Shares magazine
Plus more useful investment content and occasional promotional offers.
Market Overview
UK 350 Risers and Fallers
Risers
| Company | Price | % Chg |
|---|---|---|
| Volution Group PLC | 608.00 | 9.75 |
| Essentra PLC | 148.80 | 2.62 |
| Hammerson PLC | 31.24 | 1.63 |
| Ip Group PLC | 48.50 | 1.57 |
| Apax Global Alpha Limited | 147.20 | 1.52 |
| Centamin PLC | 153.60 | 1.39 |
Fallers
| Company | Price | % Chg |
|---|---|---|
| Dr. Martens PLC | 51.65 | -19.42 |
| Close Brothers Group PLC | 431.00 | -13.45 |
| Bridgepoint Group PLC | 339.60 | -11.38 |
| Johnson Matthey PLC | 1,470.00 | -8.53 |
| Dowlais Group PLC | 58.55 | -7.21 |
| Coats Group PLC | 98.60 | -5.37 |
Risers/fallers data from previous trading day.